SEC Form 4 · accession 0001640455-18-000007
Jounce Therapeutics, Inc. · JNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara Gayle Duncan
Director
Period of report
Jan 26, 2018
Accepted (ET)
Jan 29, 2018 · 8:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640455
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 26, 2018 | M | 4,000 | $4.21 | A | 4,000 | D | |
| Common Stock | Jan 26, 2018 | S | 4,000 | $25.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $4.21 | Jan 26, 2018 | M | 4,000 | D | — | May 9, 2026 | Common Stock | 4,000 | 46,271 | D |
Explanation of responses
- F1The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trade.
- F2The Stock Option, representing the right to purchase a total of 50,271 shares of common stock, vests in 16 equal quarterly installments following May 10, 2016.